[Mechanism and therapeutic strategy of second failure of infliximab treatment for Crohn's disease]

Nihon Shokakibyo Gakkai Zasshi. 2012 Mar;109(3):364-9.

[Article in Japanese]

Authors

Takanori Kanai¹, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Yasushi Iwao, Haruhiko Ogata, Toshifumi Hibi

Affiliation

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan.

PMID: 22398900

No abstract available

Publication types

Review

MeSH terms

Adalimumab
Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease / therapy*
Humans
Infliximab
Treatment Failure

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Infliximab
Adalimumab